Key terms
About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AKRO news
Apr 22
6:15am ET
Akero Therapeutics reinstated with a Neutral at BofA
Mar 12
9:44am ET
JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
Mar 08
7:55am ET
Akero Therapeutics’ Strong Trial Results and Market Positioning Justify Buy Rating
Mar 06
1:58pm ET
89bio price target raised to $37 from $29 at Evercore ISI
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 05
9:16pm ET
Akero Therapeutics 11M share Secondary priced at $29.00
Mar 05
6:30am ET
Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)
Mar 05
6:11am ET
Akero Therapeutics price target raised to $50 from $43 at H.C. Wainwright
Mar 04
4:25pm ET
Akero Therapeutics announces $300M common stock offering
Mar 04
12:55pm ET
Akero Therapeutics: Promising Phase IIb Results Propel Strong Buy Rating
Mar 04
12:51pm ET
Akero Therapeutics price target raised to $50 from $35 at Jefferies
Mar 04
12:50pm ET
Akero Therapeutics price target raised to $50 from $36 at Evercore ISI
Mar 04
12:45pm ET
Akero upside capped on bone mineral density questions, says Cantor
Mar 04
12:10pm ET
Akero 96-week update ‘posiitve’ for 89Bio, says Raymond James
Mar 04
7:50am ET
Akero Therapeutics to host conference call
Mar 04
6:03am ET
Akero Therapeutics reports results from Phase 2B HARMONY study
Mar 04
4:55am ET
Akero Therapeutics to host conference call
Mar 04
4:55am ET
Akero Therapeutics to host conference call
Mar 03
10:43pm ET
Akero Therapeutics to host conference call
Mar 01
12:40pm ET
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Akero Therapeutics (AKRO)
Mar 01
12:29pm ET
Akero Therapeutics price target raised to $43 from $40 at H.C. Wainwright
Feb 29
4:15pm ET
Akero Therapeutics’ Buy Rating Affirmed on Efruxifermin’s Promise for NASH Treatment
Feb 29
7:08am ET
Akero Therapeutics reports Q4 EPS (99c), consensus (86c)
Feb 26
12:02pm ET
Madrigal opportunity in MASH remains after Boehringer data, says UBS
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
1:10pm ET
Cantor biotech/biopharma analysts to hold analyst/industry conference call
Jan 31
4:55am ET
Akero Therapeutics management to meet with Cantor Fitzgerald
Jan 25
10:46am ET
Akero Therapeutics management to meet with Cantor Fitzgerald
Apr 22
8:27am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Apr 14
11:16am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Apr 06
1:16pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
AKRO Financials
Key terms
Ad Feedback
AKRO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AKRO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range